论文部分内容阅读
目的了解2型糖尿病(T2DM)合并冠心病(CHD)患者调脂治疗的达标情况。方法对6个月内接受过调脂治疗的161例合并CHD的T2DM患者进行血脂检测,并以2007年《中国2型糖尿病防治指南》为标准分析其达标情况。结果 LDL-C、HDL-C和TG水平分别为(2.71±0.67)、(1.15±0.43)和(2.06±0.87)mmol/L,经t检验,HDL-C水平达标(P>0.05),LDL-C和TG水平未达标(P均<0.05)。LDL-C、HDL-C和TG的达标率分别为33.5%、65.2%和46.6%。结论 T2DM合并CHD患者调脂治疗达标率较低,需进一步提高患者对调脂治疗的依从性和医生应用调脂药物的水平。
Objective To investigate the compliance of lipid-lowering therapy in type 2 diabetes mellitus (T2DM) patients with coronary heart disease (CHD). Methods Sixty-one patients with T2DM with CHD undergoing lipid-lowering therapy within 6 months were enrolled in this study. Their blood lipid levels were measured and their compliance with 2007 Guidelines for the Prevention and Treatment of Type 2 Diabetes in China was analyzed. Results The levels of LDL-C, HDL-C and TG were (2.71 ± 0.67), (1.15 ± 0.43) and (2.06 ± 0.87) mmol / L, respectively. -C and TG levels did not reach the standard (P <0.05). The compliance rates of LDL-C, HDL-C and TG were 33.5%, 65.2% and 46.6% respectively. Conclusions The compliance rate of lipid-lowering therapy in patients with T2DM complicated with CHD is low, and the compliance with lipid-lowering therapy and the level of lipid-lowering drugs used by doctors should be further improved.